DEVELOPMENT AND VALIDATION OF A RAPID AND SIMPLE REVERSED-PHASE HPLC METHOD FOR THE DETERMINATION OF GEMCITABINE IN HUMAN PLASMA

  • Hugo Vidal REQUIMTE/FARMA, University of Porto - Faculty of Pharmacy, Department of Drug Sciences, Laboratory of Pharmacology
  • Helena GonÇalinho REQUIMTE/FARMA, University of Porto - Faculty of Pharmacy, Department of Drug Sciences, Laboratory of Pharmacology
  • Joaquim Monteiro REQUIMTE/FARMA, University of Porto - Faculty of Pharmacy, Department of Drug Sciences, Laboratory of Pharmacology
  • JosÉ Das Neves REQUIMTE/FARMA, University of Porto - Faculty of Pharmacy, Department of Drug Sciences, Laboratory of Pharmacology
  • Bruno Sarmento REQUIMTE/FARMA, University of Porto - Faculty of Pharmacy, Department of Drug Sciences, Laboratory of Pharmacology
  • Carmen Diniz REQUIMTE/FARMA, University of Porto - Faculty of Pharmacy, Department of Drug Sciences, Laboratory of Pharmacology
  • Paula . REQUIMTE/FARMA, University of Porto - Faculty of Pharmacy, Department of Drug Sciences, Laboratory of Pharmacology

Abstract

Objective: In order to investigate the human plasma pharmacokinetics of dFdC, the objective of this work was to optimize and validate a rapid reversed-phase (RP) high-performance liquid chromatography (HPLC) method according to the guidelines of the international regulatory institutions: European Medicines Agency (EMA), Food and Drug Administration (FDA) and International Conference on Harmonization (ICH). Methods: Chromatographic runs were performed on a RP-ACE-C18 column. Mobile phase was constituted of sodium acetate buffer (pH 5) and acetonitrile, in gradient mode, at a flow rate of 1 mL/min. Gemcitabine and cytarabine (internal standard) were detected at 290 nm.Results: The method was shown to be selective, linear in the range of 0.25–10 mg/L (R2=0.9998), accurate and precise within-run and between-run as reflected by the coefficient of variation values (<15%) and the relative errors values (<15%), stable and robust to changes in the column temperature and detection UV wavelength. Detection limit and lower limit of quantification were 0.22 and 0.25 mg/L respectively.  Conclusion: The developed method is useful to measuring gemcitabine plasmatic concentrations in pharmacokinetics studies and in therapeutic drug monitoring. Objective: In order to investigate the human plasma pharmacokinetics of dFdC, the objective of this work was to optimize and validate a rapid reversed-phase (RP) high-performance liquid chromatography (HPLC) method according to the guidelines of the international regulatory institutions: European Medicines Agency (EMA), Food and Drug Administration (FDA) and International Conference on Harmonization (ICH).Methods: Chromatographic runs were performed on a RP-ACE-C18 column. Mobile phase was constituted of sodium acetate buffer (pH 5) and acetonitrile, in gradient mode, at a flow rate of 1 mL/min. Gemcitabine and cytarabine (internal standard) were detected at 290 nm.Results: The method was shown to be selective, linear in the range of 0.25–10 mg/L (R2=0.9998), accurate and precise within-run and between-run as reflected by the coefficient of variation values (<15%) and the relative errors values (<15%), stable and robust to changes in the column temperature and detection UV wavelength. Detection limit and lower limit of quantification were 0.22 and 0.25 mg/L respectively. Conclusion: The developed method is useful to measuring gemcitabine plasmatic concentrations in pharmacokinetics studies and in therapeutic drug monitoring.
Keywords: Gemcitabine, Cytarabine, Reversed-phase HPLC, Plasma.

Downloads

Download data is not yet available.

References

NCCN Non-Small Cell Lung Cancer Panel Members Non-small cell lung cancer. NCCN clinical practice guidelines in oncology version 2, 2012.
2. E Azoulay. Pulmonary involvement in patients with hematological malignacies. Springer;2011.
3. C Bowen, S Wang, H Licea-Perez. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. J Chromatography B 2009;877:2123-9.
4. O Caffo, S Fallani, E Marangon, S Nobili, MI Cassetta, V Murgia, et al. Cancer Chemother Pharmacol 2010;65:1197–202.
5. A Chang, P Ganz, D Hayes, T Kinsella, H Pass, J Schiller, et al. Strecher, Oncology: an evidence-based approach, Springer Science+Business Media. Inc 2006.
6. M Elnaggar, E Giovannetti, G Peters. Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations; Curr Pharm Des 2012. p. 28.
7. D Gesto, N Cerqueira, P Fernandes, M Ramos. Gemcitabine: a critical nucleoside for cancer therapy. Curr Med Chem 2012;19(7):1076-87.
8. LD Vainchtein, H Rosing, B Thijssen, JHM Schellens, JH Beijnen. Rapid Commun. Mass Spectrom 2007;21:2312–22.
9. B Keith, Y Xu, J L Grem. Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography. J Chromatography B 2003;785:65–72.
10. MN Kirstein, I Hassan, DE Guire, DR Weller, JW Dagit, JE Fisher, RP Remmel. High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media. J Chromatography B 2006;835:136–42.
11. C Lanz, M Fruh, W Thormann, T Cerny, BH Lauterburg. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. J Sep Sci 2007;30:1811–20.
12. E Marangon, F Sala, O Caffo, E Galligioni, M D’Incalci, M Zucchetti, Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. J Mass Spectrom 2008;43:216–23.
13. NA Parshina, TV Pleteneva, VN Baikova, MN Narimanov SA. Quantitative estimation of gemcitabine by HPLC in plasma. Tyulyan Din Pharm Chem J 2008;5:42.
14. W-X Qi, L-n Tang, A-n He, Z Shen, F Lin, Y Yao. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung 2012;19.
15. H Nakamichi, T Fujita, D Tsuji, I Atsumi, K Totsuka, R Suzuki, et al. Analysis of risk factors of drug-induced lung injury in patients receiving gemcitabine treatment. Gan To Kagaku Ryoho 2012;39(5):787-92.
16. W Lin-run, L Jian, H Ming-zhu, X Nong. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 2007;8(5):307-13.
17. W Lin-run, H Ming-zh, X Nong, S Jian-zhong, L Jian, C Jie. Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci 2005;6B(5):446-50.
18. A Ramón-Lópeza, V Escudero-Ortizb, MJ Duart-Duarta, JJ Pérez-Ruixo, B Valenzuela. Farmacocinética poblacional de gemcitabina aplicada a la personalización de su dosificación en pacientes oncológicos. Farm Hosp 2012;36:194-206.
19. GA Shabir. Validation of high-performance liquid chromatography methods for pharmaceutical analysis Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatography A 2003;987:57–66.
20. ICH Guideline Q2 (R1): Validation of Analytical Procedures: Test and Methodology;2005.
21. Guideline on bioanalytical method validation: European Medicines Agency;2011.
22. J das Neves, B Sarmento, MM Amiji, MF Bahia. Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles. J Pharm Biomed Anal 52:167.
23. JM Sonnergaard. On the misinterpretation of the correlation coefficient in pharmaceutical sciences. Int J Pharm 2006; 321:12–7.
24. MW Dong. Modern HPLC for practicing scientists John Wiley & Sons: Inc. New Jersey;2006.
25. Y Kazakevich, R Lobrutto. HPLC for Pharmaceutical Scientists, John Wiley & Sons, Inc., Hoboken: New Jersey;2007.
26. Reversed-Phase HPLC of Basic Compounds: Solving Peak Tailing Problems. Newsletter Advanced Chromatography Tecnologies. Issue One. ACE.
27. In Pub Chem Compound-National Center for Biotechnology Information, U. S. National Library of Medicine, Available at: < http: //pubchem. ncbi. nlm. nih. gov/summary/summary. cgi?cid=60750&loc=ec_rcs> (accessed 25/08/2013).
Statistics
447 Views | 1453 Downloads
How to Cite
Vidal, H., H. GonÇalinho, J. Monteiro, J. Das Neves, B. Sarmento, C. Diniz, and P. . “DEVELOPMENT AND VALIDATION OF A RAPID AND SIMPLE REVERSED-PHASE HPLC METHOD FOR THE DETERMINATION OF GEMCITABINE IN HUMAN PLASMA”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 6, no. 9, 1, pp. 59-65, https://innovareacademics.in/journals/index.php/ijpps/article/view/3200.
Section
Original Article(s)